Young-Hee Yoon

Bio: Young-Hee Yoon is an academic researcher from Asan Medical Center. The author has contributed to research in topics: Cataract surgery & Macular degeneration. The author has an hindex of 2, co-authored 2 publications receiving 877 citations.

Ranibizumab in South Korean and Taiwanese patients with age-related macular degeneration: primary outcome of the EXTEND III study.

Abstract: fluid retained in the needle lumen was estimated as 0.051 and 0.073 g, respectively, (equivalent to 51 and 73 ll) representing one and 1.5 intravitreal ranibizumab doses. The injection of rubber particles has been previously reported in patients on insulin therapy. (Asakura et al. 2001) The presence of rubber particles in intravitreal injections may lead to unexpected inflammatory reactions as well as sustained increased IOP secondary to trabecular meshwork obstruction. (Montanari et al. 1996) Latex allergy has been occasionally reported in patients injected from vials with rubber stoppers. (Vassallo et al. 1995) However, this event is unlikely in patients treated with Lucentis as the stopper is made of chlorobutyl rubber and is latex free. Even though using non-filtering needles to aspirate Lucentis from the rubber-stopper vials against the manufacturer’s instructions may result in a greater amount of available drug, this procedure may cause the introduction of rubber material into the eye and lead to unexpected local or even systemic side effects. References

Medscape

Abstract: Secret History: Return of the Black Death Channel 4, 7-8pm In 1348 the Black Death swept through London, killing people within days of the appearance of their first symptoms. Exactly how many died, and why, has long been a mystery. This Secret History documentary follows experts as they pick through the evidence and reveal why the plague killed on such a scale. And they ask, what might be coming next?

eMedicine

Abstract: eMedicine创建于1996年，由近万名临床医师作为作者或编辑参与此临床医学知识库的建设，其中编辑均是来自美国哈佛、耶鲁、斯坦福、芝加哥、德克萨斯、加州大学等各分校医学院的教授或副教授。

Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis

Abstract: Objective To evaluate the safety and efficacy of 2 doses of dexamethasone intravitreal implant (DEX implant) for treatment of noninfectious intermediate or posterior uveitis. Methods In this 26-week trial, eyes with noninfectious intermediate or posterior uveitis were randomized to a single treatment with a 0.7-mg DEX implant (n = 77), 0.35-mg DEX implant (n = 76), or sham procedure (n = 76). Main outcome measure The main outcome measure was the proportion of eyes with a vitreous haze score of 0 at week 8. Results The proportion of eyes with a vitreous haze score of 0 at week 8 was 47% with the 0.7-mg DEX implant, 36% with the 0.35-mg DEX implant, and 12% with the sham (P .05 at any visit). The incidence of cataract reported in the phakic eyes was 9 of 62 (15%) with the 0.7-mg DEX implant, 6 of 51 (12%) with the 0.35-mg DEX implant, and 4 of 55 (7%) with the sham (P > .05). Conclusions In patients with noninfectious intermediate or posterior uveitis, a single DEX implant significantly improved intraocular inflammation and visual acuity persisting for 6 months. Application to Clinical Practice Dexamethasone intravitreal implant may be used safely and effectively for treatment of intermediate and posterior uveitis. Trial Registration clinicaltrials.gov Identifier: NCT00333814.